Children with unfavorable histology Wilms tumor (WT) and metastatic disease continue to experience high mortality rates. These patients urgently require new therapies. We have recently reported Phase I data indicating excellent tolerance of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab (BV) in refractory pediatric tumors. Because this therapy has been validated in adult cancers, it may provide an attractive option for patients with aggressive WT;however, methods of assessing tumor response clinically are lacking. This is a particularly critical issue for pediatric cancer patients, in whom long-term tumor control is the goal. In our previous studies, we reported that experimental WT were initially strikingly suppressed by VEGF inhibitors. Yet consistent with clinical observations that adults treated with BV virtually all progress, we found that even highly responsive xenografts resumed growth if treatment was sustained. The mechanism of resistance to VEGF blockade is poorly understood, and clinical endpoints of resistance remain undefined. Emerging data from our lab and others suggests that tumors subjected to VEGF inhibition exhibit features of ischemic injury, including induction of damage response pathways and vessel remodeling. Further, distinct changes in gene expression, vascular assembly, and perfusion occur both acutely and chronically. For example, we have previously reported that VEGF inhibition can cause striking loss of branching vasculature and ischemia by 24 hours, whereas long-term blockade results in vessel remodeling, recovery of flow, and tumor progression. Key molecular markers of the response to vessel injury include members of gene families that are essential to angiogenesis, including integrins (alphaVbeta3), VEGF receptors (VEGFR-1 and -2), and Notch family members (Jagged-1), and mediators of the response to hypoxia (such as COX-2). High frequency ultrasound is an emerging technology that can provide rapid and longitudinal assessment of the anatomic, functional, and physiological response of WT vasculature to VEGF inhibitors. Further, the excellent sensitivity of newly available commercial scanners to sonographic contrast agents (microbubble) echo-signatures facilitates visualization of vessel architecture, quantification of blood flow, and molecular imaging of endothelial biomarkers in solid tumors. Yet this technology is still in its infancy, and further development of long-circulating and targeted microbubbles is critical for realizing its full potential as a means of evaluating dynamic changes in vessel structure and function. In particular, it is essential to develop a platform suitable for clinical point-of-care use. In these studies, we will investigate vascular remodeling during VEGF blockade using high frequency ultrasound, in the specific context of experimental WT, and using novel microbubble tools and ultrasound imaging techniques. Our goal in these studies is to relate acute and chronic molecular changes in WT angiogenesis with highly quantitative and sensitive architectural and flow characteristics and vascular biomarker expression patterns revealed by ultrasound.

Public Health Relevance

Our ultimate goal is to develop an innovative ultrasound technique to monitor and guide anti-angiogenic therapy for children with clinically aggressive Wilms tumors (WT). We will develop this technology while exploring tumor vascular changes during initial and chronic blockade of vascular endothelial growth factor (VEGF). We hypothesize that molecular changes in WT angiogenesis can be correlated with vascular changes revealed by noninvasive ultrasound.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA139173-02
Application #
7835744
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Henderson, Lori A
Project Start
2009-05-07
Project End
2011-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
2
Fiscal Year
2010
Total Cost
$228,214
Indirect Cost
Name
Columbia University (N.Y.)
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
049179401
City
New York
State
NY
Country
United States
Zip Code
10027
Sirsi, Shashank R; Flexman, Molly L; Vlachos, Fotois et al. (2012) Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. Ultrasound Med Biol 38:1019-29
Flexman, Molly L; Vlachos, Fotios; Kim, Hyun Keol et al. (2012) Monitoring early tumor response to drug therapy with diffuse optical tomography. J Biomed Opt 17:016014
Chen, Cherry C; Borden, Mark A (2010) Ligand conjugation to bimodal poly(ethylene glycol) brush layers on microbubbles. Langmuir 26:13183-94
Sirsi, Shashank; Feshitan, Jameel; Kwan, James et al. (2010) Effect of microbubble size on fundamental mode high frequency ultrasound imaging in mice. Ultrasound Med Biol 36:935-48
Sirsi, Shashank; Borden, Mark (2009) Microbubble Compositions, Properties and Biomedical Applications. Bubble Sci Eng Technol 1:3-17